PPARGC1A and cancer: Additionally, cancer cells with inactive or impaired AMPK signaling may be more sensitive to metformin treatment, as AMPK is the main energy sensor in the cell, and AMPK activation upon exposure to metformin contributes significantly to the upregulation of PGC-1α and its adaptive programs (70).